Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Matthew TJ"'
Publikováno v:
Journal of Foot and Ankle Research, Vol 15, Iss 1, Pp n/a-n/a (2022)
Abstract Background 2022 marks a decade since the profession of podiatry secured independent prescribing rights in the UK. Widely viewed as a significant milestone, its advent appeared to herald a new age of practice, with increased autonomy, a broad
Externí odkaz:
https://doaj.org/article/e991017f0a4341dd8f16cb438fc0d4f6
Autor:
Fitzpatrick, Matthew TJ1,2 (AUTHOR) m.fitzpatrick@nhs.net, Borthwick, Alan M1,2,3 (AUTHOR)
Publikováno v:
Journal of Foot & Ankle Research. 5/11/2022, Vol. 15 Issue 1, p1-7. 7p.
Autor:
Anca D. Petrescu, Juliet Venter, Daria D. Danilenko, Daniela Medina, Stephanie Grant, Su Yeon An, Elaina Williams, Patrick Mireles, Kathryn Rhodes, Matthew Tjahja, Sharon DeMorrow
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-18 (2024)
Abstract Gulf War Illness (GWI) describes a series of symptoms suffered by veterans of the Gulf war, consisting of cognitive, neurological and gastrointestinal dysfunctions. Two chemicals associated with GWI are the insecticide permethrin (PER) and t
Externí odkaz:
https://doaj.org/article/250a2c8a2d9b4aeb902e005dd886c53b
Identifying Inhibitors of -1 Programmed Ribosomal Frameshifting in a Broad Spectrum of Coronaviruses
Autor:
Munshi, Sneha, Neupane, Krishna, Ileperuma, Sandaru M, Halma, Matthew TJ, Kelly, Jamie A, Halpern, Clarissa F, Dinman, Jonathan D, Loerch, Sarah, Woodside, Michael T
Publikováno v:
Viruses, vol 14, iss 2
Recurrent outbreaks of novel zoonotic coronavirus (CoV) diseases in recent years have highlighted the importance of developing therapeutics with broad-spectrum activity against CoVs. Because all CoVs use -1 programmed ribosomal frameshifting (-1 PRF)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::08c6009666eb9fdfccee847958065591
https://escholarship.org/uc/item/7zx6p427
https://escholarship.org/uc/item/7zx6p427
Publikováno v:
Journal of Cerebral Blood Flow & Metabolism; Aug2013, Vol. 33 Issue 8, p1295-1306, 12p
Autor:
Wang BT; IGM Biosciences Inc., Mountain View, California., Kothambawala T; IGM Biosciences Inc., Mountain View, California., Wang L; IGM Biosciences Inc., Mountain View, California., Matthew TJ; IGM Biosciences Inc., Mountain View, California., Calhoun SE; IGM Biosciences Inc., Mountain View, California., Saini AK; IGM Biosciences Inc., Mountain View, California., Kotturi MF; IGM Biosciences Inc., Mountain View, California., Hernandez G; IGM Biosciences Inc., Mountain View, California., Humke EW; IGM Biosciences Inc., Mountain View, California., Peterson MS; IGM Biosciences Inc., Mountain View, California., Sinclair AM; IGM Biosciences Inc., Mountain View, California., Keyt BA; IGM Biosciences Inc., Mountain View, California. bkeyt@igmbio.com.
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2021 Dec; Vol. 20 (12), pp. 2483-2494. Date of Electronic Publication: 2021 Oct 28.